Deep brain stimulation (DBS) is the procedure of choice for Parkinson’s disease (PD). It has been used in PD patients younger than 70 years because of better perceived intra- and postoperative outcomes than in patients 70 years or older. However, previous studies with limited follow-up have demonstrated benefits associated with the treatment of elderly patients. This study aims to evaluate the long-term outcomes in elderly PD patients treated with DBS in comparison with a younger population.
PD patients treated with DBS at the authors’ institution from 2008 to 2014 were divided into 2 groups: 1) elderly patients, defined as having an age at surgery ≥ 70 years, and 2) young patients, defined as those < 70 years at surgery. Functional and medical treatment outcomes were evaluated using the Unified Parkinson’s Disease Rating Scale part III (UPDRS III), levodopa-equivalent daily dose (LEDD), number of daily doses, and number of anti-PD medications. Study outcomes were compared using univariate analyses, 1-sample paired t-tests, and 2-sample t-tests.
A total of 151 patients were studied, of whom 24.5% were ≥ 70 years. The most common preoperative Hoehn and Yahr stages for both groups were 2 and 3. On average, elderly patients had more comorbidities at the time of surgery than their younger counterparts (1 vs 0, p = 0.0001) as well as a higher average LEDD (891 mg vs 665 mg, p = 0.008). Both groups experienced significant decreases in LEDD following surgery (elderly 331.38 mg, p = 0.0001; and young 108.6 mg, p = 0.0439), with a more significant decrease seen in elderly patients (young 108.6 mg vs elderly 331.38 mg, p = 0.0153). Elderly patients also experienced more significant reductions in daily doses (young 0.65 vs elderly 3.567, p = 0.0344). Both groups experienced significant improvements in motor function determined by reductions in UPDRS III scores (elderly 16.29 vs young 12.85, p < 0.0001); however, reductions in motor score between groups were not significant. Improvement in motor function was present for a mean follow-up of 3.383 years postsurgery for the young group and 3.51 years for the elderly group. The average follow-up was 40.6 months in the young group and 42.2 months in the elderly group.
This study found long-term improvements in motor function and medication requirements in both elderly and young PD patients treated with DBS. These outcomes suggest that DBS can be successfully used in PD patients ≥ 70 years. Further studies will expand on these findings.
ABBREVIATIONSDBS = deep brain stimulation; HY = Hoehn and Yahr; LEDD = levodopa-equivalent daily dose; MoCA = Montreal Cognitive Assessment; PD = Parkinson’s disease; STN = subthalamic nucleus; UPDRS III = Unified Parkinson’s Disease Rating Scale part III.
BronsteinJM, TagliatiM, AltermanRL, LozanoAM, VolkmannJ, StefaniA, : Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. 68:165, 20112093793610.1001/archneurol.2010.260)| false
CozacVVEhrenspergerMMGschwandtnerUHatzFMeyerAMonschAU: Older candidates for subthalamic deep brain stimulation in Parkinson’s disease have a higher incidence of psychiatric serious adverse events. Front Aging Neurosci8:1322016
CozacVV, EhrenspergerMM, GschwandtnerU, HatzF, MeyerA, MonschAU, : Older candidates for subthalamic deep brain stimulation in Parkinson’s disease have a higher incidence of psychiatric serious adverse events. 8:132, 201610.3389/fnagi.2016.0013227375478)| false
DafsariHS, RekerP, StalinskiL, SilverdaleM, RizosA, AshkanK, : Quality of life outcome after subthalamic stimulation in Parkinson’s disease depends on age. 33:99–107, 20182915086010.1002/mds.27222)| false
DeLongMR, HuangKT, GallisJ, LokhnyginaY, ParenteB, HickeyP, : Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. 71:1290–1295, 20142515548110.1001/jamaneurol.2014.1272)| false
DerostPP, OuchchaneL, MorandD, UllaM, LlorcaPM, BargetM, : Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?68:1345–1355, 200710.1212/01.wnl.0000260059.77107.c2)| false
DorseyER, ConstantinescuR, ThompsonJP, BiglanKM, HollowayRG, KieburtzK, : Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. 68:384–386, 20071708246410.1212/01.wnl.0000247740.47667.03)| false
EskandarENFlahertyACosgroveGRShinobuLABarkerFGII: Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample. J Neurosurg99:863–8712003
EskandarEN, FlahertyA, CosgroveGR, ShinobuLA, BarkerFGII: Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample. 99:863–871, 200310.3171/jns.2003.99.5.0863)| false
FasanoA, RomitoLM, DanieleA, PianoC, ZinnoM, BentivoglioAR, : Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. 133:2664–2676, 20102080220710.1093/brain/awq221)| false
LenzFASchniderSTaskerRRKwongRKwanHDostrovskyJO: The role of feedback in the tremor frequency activity of tremor cells in the ventral nuclear group of human thalamus. Acta Neurochir Suppl (Wien)39:54–561987
LenzFA, SchniderS, TaskerRR, KwongR, KwanH, DostrovskyJO, : The role of feedback in the tremor frequency activity of tremor cells in the ventral nuclear group of human thalamus. 39:54–56, 1987331438710.1007/978-3-7091-8909-2_15)| false
LewisSJ, FoltynieT, BlackwellAD, RobbinsTW, OwenAM, BarkerRA: Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. 76:343–348, 200510.1136/jnnp.2003.03353015716523)| false
MathkourM, GarcesJ, ScullenT, HannaJ, Valle-GilerE, KahnL, : Short and long-term outcomes of deep brain stimulation in Parkinson’s disease patients 70-years and older. 97:247–252, 201710.1016/j.wneu.2016.06.001)| false
OkunMSGalloBVMandyburGJagidJFooteKDRevillaFJ: Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurol11:140–1492012
WeaverFM, FollettK, SternM, HurK, HarrisC, MarksWJJr, : Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. 301:63–73, 200910.1001/jama.2008.92919126811)| false
WilliamsAGillSVarmaTJenkinsonCQuinnNMitchellR: Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol9:581–5912010
WilliamsA, GillS, VarmaT, JenkinsonC, QuinnN, MitchellR, : Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. 9:581–591, 201010.1016/S1474-4422(10)70093-4)| false
ZhuXLChanDTLauCKPoonWSMokVCChanAY: Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. World Neurosurg82:987–9932014
ZhuXL, ChanDT, LauCK, PoonWS, MokVC, ChanAY, : Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. 82:987–993, 201410.1016/j.wneu.2014.08.051)| false
ZibettiM, MerolaA, RizziL, RicchiV, AngrisanoS, AzzaroC, : Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. 26:2327–2334, 20112201275010.1002/mds.23903)| false